PubMed HealthSearch

PubMed · 7430358

Processing haematological data on a dedicated computer.

Abstract

A system of processing the laboratory data of a busy haematology department serving a teaching group of hospitals and the general practitioners of the district is described. The system, which has been in routine use for over two years, is based on a dedicated CTL8030 computer sited in the laboratory utilising Lynwood visual display units (VDUs) for both input and access to the data files. Data from the Coulter 'S' is fed by an interface to the computer and to other data handling modules. Manual test results are entered via VDUs, mainly by laboratory staff who also validate all data. Access is available to all data for answering telephone requests. Data are retained on the disc file for 48 hours only, and cumulative reporting was not planned into the system as deliberate policy. Quality control of the Coulter 'S' output is maintained both throughout the day and retrospectively at the end of each working day using both whole blood patient blood transfusion profiles, a record of blood and product usage, worksheets, quality control information, end-of-day listing in alphabetical order plus statistical information for administrative purposes. Since its introduction the system has been remarkably free from breakdown as a result of hardware failure. A number of fail safe/fallbacks have been included in the system.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M G Nelson, C L Farrington, J D Rogers, G W Purdy. 1980. Processing haematological data on a dedicated computer.. https://doi.org/10.1136/jcp.33.10.926

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life.

We have previously reported that recombinant human granulocyte colony-stimulating factor was well tolerated and resulted in sustained neutrophilia and improvement of neutrophil functions in newborn infants with presumed sepsis. We now report a 2-year follow-up on 21 of the initial cohort of 28 patients. Treatment with recombinant human granulocyte colony-stimulating factor in neonates with presumed sepsis was not associated with any long-term adverse hematologic, immunologic, or developmental effects.

Blood Cell Count